About LumiraDx
LumiraDx is a Healthcare company based in Waltham (United States) founded in 2014 by Sumit Nagpal, and was acquired by Roche in January 2024. Cloud based diagnostics platform for point of care diagnosing. LumiraDx has raised $703.91 million across 9 funding rounds from investors including Roche, Capital One and Gates Foundation. The company has 9 employees. Its chief executive, as recorded, is Sumit Nagpal. Its Indian entity Lumiradx Healthcare Private Limited reported revenue of ₹3.81 Cr. LumiraDx offers products and services including LumiraDx Instrument and LumiraDx Assays. Its focus areas include Diversified Diagnostics, Tests and Point Of Care. Its competitors include LightDeck Diagnostics, Abaxis and ProciseDx; 2 of its 3 listed competitors have raised funding.
Company details
LumiraDx a healthcare solutions care management company specializing in the comprehensive support of individuals with chronic disease. The flagship software solutions called Consult allow health and social care providers to view and manage patient records that are always joined up across all venues of care, from the doctors office to a patients home. The patient-facing version of this software Engage allows individuals to view, manage, and share their own history from across all venues of care. Their platform also connects with a growing list of home and point-of-care diagnostic devices and personal biometric devices that record real-time activity including continuous heart rate, surface temperature, posture, sleep, stress levels and integrates this data into individual longitudinal records.
- Headquarters Waltham, United States
- Employees 9
- Founders Sumit Nagpal
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website lumiradx.com
- Social LinkedIn X Facebook
- Acquired by Roche (Jan 2024)
- Legal Name Lumiradx Healthcare Private Limited
- Date of Incorporation 07 Jul, 2021
- Jurisdiction Mumbai, Maharashtra, India
- Indian entity revenue₹3.81 Cr
FY 2024 · +16% YoY
- Indian entity net profit₹50.1 Lakh
FY 2024 · 13% margin
- Indian entity EBITDA₹52.6 Lakh
FY 2024 · 14% margin
- Total Equity Funding$703.91M (USD)
in 9 rounds
- Latest Funding Round$14.2M (USD), Grant
Dec 2022
- InvestorsRoche
& 3 more
- Employee Count9
- Acquired byRoche
(Jan 2024)
Associated legal entities of LumiraDx
LumiraDx operates through Lumiradx Healthcare Private Limited (under liquidation). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Lumiradx Healthcare Private Limited CIN U33309MH2021FTC363513 | Under Liquidation | 07 Jul 2021 | Mumbai, Maharashtra | ₹3.8 Cr | 9 | 4 | View details |
Products & Services of LumiraDx
LumiraDx offers a comprehensive portfolio of products and services, including LumiraDx Instrument and LumiraDx Assays.
Portable system for point-of-care assays and health testing
Tests for detecting diseases from various sample types
Funding Insights of LumiraDx
LumiraDx has successfully raised a total of $703.91M across 9 strategic funding rounds. The most recent funding activity was a Grant round of $14.2 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $703.91M
- Total Rounds 9
- Last Round Grant — $14.2M
- First Round $42.63M
(Oct 2016)
- Investors Count 3
All 9 funding rounds of LumiraDx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $14.2M | Grant | – | – | |
| Apr 2021 | $400M | Debt – Conventional | – | – | |
| Dec 2020 | $164M | Series D | – | – | – |
| May 2020 | $150M | Series C | – | – | – |
| Feb 2020 | $75.16M | Debt – Conventional | – | – | – |
| Sep 2019 | $76.68M | Series C | – | – | – |
| Jan 2019 | $270M | Series C | – | – | – |
| Dec 2016 | $613,156 | Series B | – | – | – |
| Oct 2016 | $42.63M | Series B | – | – | – |
4 investors in total: 4 institutional.
Investors in LumiraDx
LumiraDx has secured backing from 4 investors, including institutional investors. Prominent investors backing the company include Roche, Capital One and Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States | |
Provider of marketing services to biopharma sector | 2016 | bpcruk.com | United Kingdom | |
Provider of loans, credit cards, and savings services | 1988 | capitalone.com | Mclean, United States | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for LumiraDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Lumiradx Healthcare Private Limited (LumiraDx)
Lumiradx Healthcare Private Limited is the primary company behind LumiraDx. The board of Lumiradx Healthcare Private Limited currently have 4 directors; the longest-serving is Yogesh Singh, appointed in 2021. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Yogesh Singh DIN 09428161 | Director | 08 Dec 2021 | 4 yrs 10 mo | Lumiradx Healthcare Private Limited |
| Veronique Yuvonne Ameye DIN 09512069 | Director | 23 Feb 2022 | 4 yrs 8 mo | Lumiradx Healthcare Private Limited |
| David Walton DIN 09512071 | Director | 23 Feb 2022 | 4 yrs 8 mo | Lumiradx Healthcare Private Limited |
| Ravi Sharma DIN 00004567 | IRP/RP/Liquidator | 20 Nov 2024 | 1 yr 11 mo | Lumiradx Healthcare Private Limited |
People of LumiraDx
16 people are tracked at LumiraDx (9 in leadership, 6 in board & advisors, 1 in team); the tracked headcount is 9.
| Name | Role | Group |
|---|---|---|
Sumit Nagpal | Co-Founder & CEO | Leadership |
Ron Zwanziger | CEO, Chairman & Director | Leadership |
David Scott | Chief Technology Officer & Director | Leadership |
| Chief Commercial Officer | Leadership | |
Dorian LeBlanc | Chief Financial Officer | Leadership |
| Deputy CEO & General Counsel | Leadership | |
Jerry McAleer | Chief Scientist & Director | Leadership |
Sarah Rova McIpd | Director - People & Culture | Leadership |
Jill Brown Msc | Senior Director, People Operations | Leadership |
Donald Berwick | Director | Board & advisors |
Lurene Joseph | Director | Board & advisors |
Gerald L. Chan | Director | Board & advisors |
Bruce Keogh | Director | Board & advisors |
Lu Huang | Director | Board & advisors |
Troyen A. Brennan | Director | Board & advisors |
James Liu | Principal Engineer | Team |
Complete people profiles for LumiraDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of LumiraDx
Figures of Lumiradx Healthcare Private Limited, the primary company behind LumiraDx, for FY 2024. Revenue was ₹3.81 Cr (+16% year on year). Net profit was ₹50.1 Lakh (13% margin). EBITDA was ₹52.6 Lakh (14% margin).
- ₹3.81 CrRevenue · FY 2024 · +16% YoY
- ₹50.1 LakhNet profit · 13% margin
- ₹52.6 LakhEBITDA · 14% margin
- ₹65 LakhPaid-up capital
- 9Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Lumiradx Healthcare Private Limited are on its company page.
Detailed financial statements for LumiraDx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of LumiraDx
5 dated milestones of LumiraDx across 10 years, from founding to its latest funding, stage changes and deals.
- Founded LumiraDx is founded.
- Funding First funding round of $42.6M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $14.2M.
- Exit Acquired by Roche.
Competitors of LumiraDx
LumiraDx has 3 listed competitors in our database, 2 of them funded. They include LightDeck Diagnostics, Abaxis and ProciseDx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lightdeckdx.com | 2009 | Boulder, United States | $57.02M | Point-of-care diagnostic devices for multiplex assays are developed. | ||
| abaxis.com | 1989 | California, United States | 564 | Diagnostics company offering a comprehensive line of on-site diagnostic instruments and rapid tests | ||
| procisedx.com | 2018 | San Diego, United States | $8.96M | Point-of-care diagnostic devices for immunoassay tests are provided to clinicians. |
Detailed competitors of LumiraDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of LumiraDx
Websites that share an audience with LumiraDx (lumiradx.com).
Websites whose visitors overlap most with LumiraDx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
roche-diagnostics.jp | roche-diagnostics.jp | 100% | #1,530,157 | – | |
medicalexpo.fr | medicalexpo.fr | 94% | #248,166 | – | |
radiometer.fr | radiometer.fr | 69% | #3,170,581 | – | |
| lumiraventures.com | 57% | #3,408,753 | View details | ||
cardio-online.fr | cardio-online.fr | 57% | #447,215 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for LumiraDx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Diagnostics & Lab Tech
3 companies that operate in the same segment as LumiraDx (Diagnostics & Lab Tech) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
At-home health tests for biomarkers, nutrition, and hormone analysis. | 2014 | Austin, Texas, United States | USD 330 M | 336 | ||
Blood testing services are offered using finger-prick microsamples. | 2017 | Austin, Texas, United States | USD 37.7 M | |||
Manufactures clinical diagnostic test kits | 1971 | Irvine, California, United States | USD 4.45 M | 54 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lumiradx
Complete news archive for LumiraDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about LumiraDx
LumiraDx was founded in 2014 and raised its 1st funding round 2 years after it was founded.
LumiraDx is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Sumit Nagpal is the CEO of LumiraDx, as recorded in our data. They have also founded this company.
LumiraDx is a funded company, having raised a total of $703.91M across 9 funding rounds to date. The company's 1st funding round was a Series B of $42.63M, raised on Oct 2016.
LumiraDx has 9 employees.
The primary company behind LumiraDx, Lumiradx Healthcare Private Limited, reported revenue of ₹3.81 Cr for FY 2024, up 16% year on year.
LumiraDx a healthcare solutions care management company specializing in the comprehensive support of individuals with chronic disease. The flagship software solutions called Consult allow health and social care providers to view and manage patient records that are always joined up across all venues of care, from the doctors office to a patients home. The patient-facing version of this software Engage allows individuals to view, manage, and share their own history from across all venues of care. Their platform also connects with a growing list of home and point-of-care diagnostic devices and personal biometric devices that record real-time activity including continuous heart rate, surface temperature, posture, sleep, stress levels and integrates this data into individual longitudinal records.
LumiraDx's top competitors include Abaxis, LightDeck Diagnostics and ProciseDx.
LumiraDx offers LumiraDx Instrument and LumiraDx Assays.
LumiraDx has 4 investors. Key investors include Roche, Capital One, Gates Foundation, and bpcruk.
LumiraDx operates through Lumiradx Healthcare Private Limited.
Yes. LumiraDx was acquired by Roche in January 2024.